BLUE News and Press, bluebird bio Inc. From 12/07/20

At the American Society of Hematology annual meeting over the weekend, Johnson & Johnson (JNJ -0.5%) posted attention-getting data on a pair of approaches to multiple myeloma. One study confirmed the company's cilta-cel as the most efficacious CAR-T therapy, with more than three-quarters ...

All patients who achieved transfusion independence continue to remain transfusion free in ongoing long-term follow-up study 87% (13/15) of pediatric patients in Phase 3 studies achieved transfusion independence with median weighted average hemoglobin of 11.3 (9.4 – 12.8...

Longer-term data from Phase 1 CRB-401 study evaluating ide-cel in relapsed and refractory multiple myeloma show ongoing deep and durable responses and median overall survival of 34.2 months 1 Analyses from pivotal KarMMa study show clinically meaningful health-relate...

Magenta Therapeutics (MGTA) and bluebird bio (BLUE) have entered into clinical trial collaboration to evaluate MGTA-145, a CXCR2 agonist, in combination with plerixafor, a CXCR4 antagonist, for mobilization and collection of stem cells in patients with sickle cell disease.Under...

Magenta Therapeutics (NASDAQ: MGTA) and bluebird bio, Inc. (NASDAQ: BLUE) today announced an exclusive clinical trial collaboration to evaluate the utility of MGTA-145, in combination with plerixafor, for mobilization and collection of stem cells in adults and adolescents with sickl...

bluebird bio, Inc. (NASDAQ: BLUE) today announced that members of the management team will participate in the following upcoming investor conferences: Cowen 2020 IO Next Summit, Friday, November 13, at 11:15 am ET Barclays Gene Editing & Gene Therapy Summit, Monday, Novemb...

Shares of bluebird bio (NASDAQ: BLUE) recently took a pounding after the company's lead candidate hit a snag that investors find all too familiar. The company will no longer be applying for approval of bb1111 as a treatment for sickle cell disease (SCD) in the second half of 2021 as...

Shares of bluebird bio (NASDAQ: BLUE) are down 14% today after releasing third-quarter earnings yesterday. It wasn't so much the earnings that investors are reacting to; for the record, the company lost $195 million on revenue of $19.3 million. Instead, investors are rightfully upse...

Gainers: Oncternal Therapeutics (ONCT) +131%, Aptevo Therapeutics (APVO) +42%, Aurora Cannabis (ACB) +36%, Tilray (TLRY) +29%, Akerna (KERN) +26%.Losers: Clovis Oncology (CLVS) -21%, bluebird bio (BLUE) -17%, Lannett Compan...

Gainers: Altus Midstream (ALTM) +150%.Hall of Fame Resort & Entertainment (HOFV) +118%.Oncternal Therapeutics (ONCT) +82%.Upwork (UPWK) +41%.Aptevo Therapeutics (APVO) +40%.Resideo Technologies (REZI) +35%.Aurora Cannabis (ACB) +34%.Kaixin Auto (KXIN) +33%.Falcon Minerals (...